Theriva Biologics Inc

Theriva Biologics Inc. is a clinical-stage company headquartered in Rockville, Maryland. The company employs 21 people and has generated over $10,000 in revenue. Theriva Biologics develops therapeutics for diseases with high unmet medical needs. Their focus areas include oncology and gastrointestinal health. The company's lead candidates include VCN-01, an oncolytic adenovirus designed to target tumor cells; SYN-004 (ribaxamase), which aims to protect the gut microbiome during antibiotic treatment; and SYN-020, a recombinant enzyme intended to treat both local and systemic diseases. Theriva Biologics acquired VCN Biosciences, S.L. to expand its oncology capabilities. This acquisition brought a novel oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery. You can learn more about Theriva Biologics by visiting their website at therivabio.com.